About Eikon Therapeutics
Operator of a drug discovery and development platform intended to offer a novel treatment for life-threatening diseases.
Operator of a drug discovery and development platform intended to offer a novel treatment for life-threatening diseases.
Total raised
$1.2B
Last stage
Series D
Investors
Xavier Darzacq
Served as interim CTO during the company's first year; scientist involved in live-cell imaging research.
LinkedInEric Betzig
Nobel Prize-winning physicist (Chemistry, 2014) and UC Berkeley scientist who pioneered super-resolution fluorescence microscopy.
Robert Tjian
Biochemist at the University of California, Berkeley and former President of the Howard Hughes Medical Institute.
Luke Lavis
Researcher known for contributions to fluorescent dye chemistry and single-molecule imaging technologies used in Eikon's discovery platform.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.